In rats with pilocarpine-induced epilepsy, Tropisetron notably reduced spontaneous recurrent seizure frequency compared with the epilepsy group. Tropisetron also decreased target-platform latency during visible-platform Morris water maze training in this model. In Tg AD mice, Tropisetron significantly decreased cortical and hippocampal Aβ levels compared with saline-treated controls. In rats undergoing trauma-hemorrhage and resuscitation, Tropisetron attenuated increases in plasma AST and ALT levels compared with vehicle-treated trauma-hemorrhage controls. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Tropisetron reduces spontaneous seizure frequency in epileptic rats
Animal study · Male Sprague–Dawley rats; pilocarpine‐induced epileptic rat model; n = 8 [1]
Male Sprague–Dawley rats with pilocarpine-induced epilepsy received Tropisetron by intraperitoneal injection at 3 mg/kg/day for 3 weeks following the onset of spontaneous recurrent seizures. Treatment notably reduced seizure frequency compared with the epilepsy group.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- daily; for 3 weeks following the onset of spontaneous recurrent seizures (SRS)
- Vehicle
- saline
- Tropisetron 3 mg/kg/day
- Model: Male Sprague–Dawley rats; pilocarpine‐induced epileptic rat model; n = 8
Methods and source locations
Compound reported in the paper: Tropisetron
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Experimental Procedures > Animals (S1); Materials and Methods > Experimental Procedures > The Pilocarpine‐Induced Epileptic Rat Model (S4, S5, S6, S9); Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S12, S16, S17); Materials and Methods > Monitoring of Spontaneous Recurrent Seizures (S23); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S79); FIGURE 1 legend (S159)
frequency, severity, and duration of spontaneous seizures: frequency, severity, and duration of spontaneous seizures; comparator: epilepsy group — Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S17); Materials and Methods > Monitoring of Spontaneous Recurrent Seizures (S23); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S79); FIGURE 1 legend (S159)
Tropisetron 3 mg/kg/day · Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S17); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S79); FIGURE 1 legend (S159)
Tropisetron decreases brain Aβ levels in Tg AD mice
Animal study · Tg AD mice (5.0–5.5-month-old) [2]
Tg AD mice received Tropisetron intraperitoneally at 0.5 mg/kg/day for 8 consecutive weeks. Immunoblot analysis showed a significant decrease in cortical and hippocampal Aβ levels compared with saline-treated Tg AD controls.
Conditions shared by the study groups
- Route
- intraperitoneally injected
- Treatment course
- for 8 consecutive weeks
- Vehicle
- sterile normal saline
- Tropisetron 0.5 mg/kg/day
- Model: Tg AD mice (5.0–5.5-month-old)
Methods and source locations
Compound reported in the paper: Tropisetron
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Chronic tropisetron treatment (S14, S15, S16); Results > Chronic tropisetron treatment diminishes Aβ plaque levels and mitigates glial activation and neuroinflammation in Tg AD mice (S104)
Immunoblot analysis: Immunoblot analysis; comparator: NS-treated Tg AD groups (n = 8) — Methods > Chronic tropisetron treatment (S16); Results > Chronic tropisetron treatment diminishes Aβ plaque levels and mitigates glial activation and neuroinflammation in Tg AD mice (S104)
Tropisetron 0.5 mg/kg/day · Methods > Chronic tropisetron treatment (S16); Results > Chronic tropisetron treatment diminishes Aβ plaque levels and mitigates glial activation and neuroinflammation in Tg AD mice (S104)
Tropisetron and Plasma AST and ALT After Trauma-Hemorrhage
Animal study · male Sprague-Dawley rats; trauma-hemorrhage; n = 8 rats in each group [3]
Male Sprague-Dawley rats undergoing trauma-hemorrhage and resuscitation received intravenous Tropisetron. Treatment attenuated the trauma-hemorrhage-induced increase in plasma AST and ALT levels compared with the trauma-hemorrhage vehicle group.
Conditions shared by the study groups
- Route
- intravenously
- Treatment course
- Thirty minutes before the end of the resuscitation period
- Vehicle
- about 0.2 mL, 10% DMSO
- Tropisetron 1 mg/kg
- Model: male Sprague-Dawley rats; trauma-hemorrhage; n = 8 rats in each group
Methods and source locations
Compound reported in the paper: Tropisetron
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Experimental Groups (S8, S9); Materials and Methods > Rat Trauma-Hemorrhagic Shock Model (S15, S23); Results > Alteration of Plasma AST and ALT Levels (S58); Figure 2 legend (S91)
plasma AST and ALT levels: plasma AST and ALT levels; comparator: an equal volume of the vehicle — Results > Alteration of Plasma AST and ALT Levels (S58)
Tropisetron 1 mg/kg · Materials and Methods > Experimental Groups (S9); Materials and Methods > Rat Trauma-Hemorrhagic Shock Model (S23); Results > Alteration of Plasma AST and ALT Levels (S58)
Tropisetron decreases platform latency in epileptic rats
Animal study · Male Sprague–Dawley rats; pilocarpine‐induced epileptic rat model; n = 8 [1]
Male Sprague–Dawley rats with pilocarpine-induced epilepsy received Tropisetron by intraperitoneal injection at 3 mg/kg/day for 3 weeks following the onset of spontaneous recurrent seizures. Treatment decreased latency to reach the target platform during visible-platform Morris water maze training compared with the epilepsy group.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- daily; for 3 weeks following the onset of spontaneous recurrent seizures (SRS)
- Vehicle
- saline
- Tropisetron 3 mg/kg/day
- Model: Male Sprague–Dawley rats; pilocarpine‐induced epileptic rat model; n = 8
Methods and source locations
Compound reported in the paper: Tropisetron
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Experimental Procedures > Animals (S1); Materials and Methods > Experimental Procedures > The Pilocarpine‐Induced Epileptic Rat Model (S4, S5, S6, S9); Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S12, S16, S17); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S82); FIGURE 1 legend (S160)
The latency to reach the underwater platform was evaluated using the Morris water maze: The latency to reach the underwater platform was evaluated using the Morris water maze; comparator: epilepsy group — Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S17); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S82); FIGURE 1 legend (S160)
Tropisetron 3 mg/kg/day · Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S17); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S82); FIGURE 1 legend (S160)